Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced the pricing of its underwritten public offering of 17,242,000 shares of its common stock at a price to the public of $14.50 per share.
